This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Hawaii
Licensed Hawaii practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida by overnight air with a Certificate of Analysis and lot traceability on every vial. Hawaii buyers need their own professional license and NPI; wholesale licensure is the supplier’s side of the transaction, not the purchaser’s.
Hawaii writes its wholesale drug distributor license around physical presence: the Board of Pharmacy’s own application instructions state that a distributor licensed in its home state with no facility, office, or vendor-managed inventory in Hawaii does not need the Hawaii license. The practical questions for a Hawaii practice are therefore elsewhere: who may perform and delegate, how the general excise tax treats resale, and how island delivery actually times out.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Hawaii? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Hawaii
ExaVeyra ships to licensed practices in all 50 states, Hawaii included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Hawaii professional license in good standing, verifiable through MyPVL, the DCCA Professional and Vocational Licensing search portal.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Hawaii resale certificate if the practice is purchasing for resale rather than for use in its own operations: Hawaii levies a general excise tax on the seller rather than a sales tax, and the certificate is what applies the wholesale rate. Registration runs through the Department of Taxation.
How the state permits wholesale distribution
Hawaii licenses wholesale prescription drug distributors through the Board of Pharmacy, within the Department of Commerce and Consumer Affairs, and no license issues until the Department of Health, Food and Drug Branch has inspected the facility. The regime covers handling, distributing, or storing prescription pharmaceuticals, medical gases, and devices that contain or accompany prescription drugs, to persons other than a consumer or patient. The distinctive feature is what triggers it: the license attaches to operating or establishing wholesale distribution within the State of Hawaii, and the Board’s application instructions state that an entity licensed in its state of domicile with no facility, office, or vendor-managed inventory located in Hawaii is not required to obtain it. Either way the obligation sits with the distributor, not with the purchasing practice.
Haw. Rev. Stat. ch. 461; Haw. Admin. R. tit. 16, ch. 95 · Hawaii Board of Pharmacy, Department of Commerce and Consumer Affairs
Hawaii regenerative-medicine law
Hawaii has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
No Hawaii statute addresses unapproved regenerative therapy, so federal law is the only layer. Hawaii has no stem cell authorization law of the Florida, Texas, or Georgia kind, no disclosure law of the California kind, and no documentation statute of the Tennessee kind. Practice in this area is governed by the medical licensing statute, the nursing statute in HRS chapter 457, and the boards within the Department of Commerce and Consumer Affairs that administer them, alongside federal law.
How this applies to exosomes
Hawaii has no stem cell statute of any kind, so there is no state definition to read exosomes into or out of, and an ocean between a practice and the mainland changes nothing about the regulatory layer that applies: it is federal everywhere. Exosomes are acellular extracellular vesicles rather than stem cells, and even the state statutes that do exist elsewhere are written around cells and tissues. Exosome products in Hawaii are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation accompanying every shipment.
Who can handle product in a Hawaii practice
Because qualified advanced practice registered nurses hold independent authority in Hawaii, there are two workable structures rather than one. An APRN-led practice can evaluate and order within APRN scope. A physician-led practice delegates conventionally, and a medical director is still needed where a procedure falls outside APRN scope or where a payer requires one. All the professions involved are licensed within the Department of Commerce and Consumer Affairs, so verification runs through the single MyPVL portal.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians and osteopathic physicians licensed by the Hawaii Medical Board may perform medical acts within their scope and are the source of any delegation to staff who do not hold independent authority. The same board licenses physician assistants. |
| NP / APRN | Hawaii recognizes advanced practice registered nurses as independently practicing licensees under HRS chapter 457, with prescriptive authority granted by the Board of Nursing to qualified APRNs, who may diagnose, prescribe, and institute therapy within the Board’s requirements. Act 169 of 2009 rewrote the chapter to this effect, so an APRN-led practice can evaluate and order within its own scope. |
| PA | Physician assistants are licensed by the Hawaii Medical Board and practice within the scope their supervising physician establishes under the board’s rules. |
| RN | Registered nurses may perform delegated treatments within their scope and under an order from a provider with authority to issue one. An RN does not evaluate the patient or set the treatment plan. |
Good faith examination
Hawaii expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Where an advanced practice registered nurse holds independent authority, that provider can be the APRN. Confirm current expectations with the Hawaii Medical Board and the Hawaii Board of Nursing, since this area is governed by board interpretation rather than a single statute.
Ownership and clinic licensing
Hawaii’s medical licensing statute requires that medicine be practiced by licensed persons, and published summaries commonly describe Hawaii as applying a corporate practice doctrine through that requirement rather than through a bright-line ownership statute. Professional entities and management services arrangements are the usual structures, and because the position rests on interpretation rather than an explicit rule, ownership structure here is a question for Hawaii counsel rather than one a guide should answer with a percentage.
Cold chain into Hawaii
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Hawaii order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Honolulu | Honolulu | Largest Hawaii market, with the deepest aesthetic and dermatology coverage in the islands. |
| Kailua | Honolulu | Windward Oahu market served on the Honolulu lane. |
| Wailuku and Kahului | Maui | Central Maui hub where the island’s clinical practices concentrate. |
| Kailua-Kona | Hawaii | West Hawaii Island market with resort-adjacent concierge practices. |
| Hilo | Hawaii | East Hawaii Island market anchored by the island’s largest hospital. |
| Lihue | Kauai | Kauai’s commercial center and air freight gateway. |
- Hawaii orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Every shipment arrives with the manufacturer’s handling instructions and the Certificate of Analysis for its lot.
- Shipments to Hawaii travel by overnight air from Florida. Honolulu addresses generally see the standard timeline once an order dispatches; neighbor island addresses can add a connection within the carrier network, so Maui, Kauai, and Hawaii Island practices order early in the week.
Wholesale exosome supply by city in Hawaii
Each city page covers local receiving conditions, delivery disruptions and business license rules for Hawaii practices in that area.
Practice types we supply in Hawaii
Hawaii licensing and verification
Hawaii Medical Board
Licenses physicians, osteopathic physicians, and physician assistants; verification through MyPVL.
Hawaii Board of Nursing
Licenses RNs, LPNs, and APRNs, and grants APRN prescriptive authority.
Hawaii Board of Pharmacy
Issues the wholesale prescription drug distributor license for in-state facilities.
Hawaii Department of Health, Food and Drug Branch
Inspects wholesale drug facilities before the Board of Pharmacy issues a license.
Hawaii Department of Taxation
General excise tax registration and resale certificates.
Hawaii sourcing questions
- Does Hawaii have a stem cell law?
- No. Hawaii has no stem cell authorization law, disclosure law, or documentation statute, so exosome products there are governed by federal law, under which no exosome product is FDA-approved for administration to humans. Practice questions run through the medical and nursing statutes and the boards within the Department of Commerce and Consumer Affairs.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA has issued a public safety notification saying so. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- Why does Hawaii’s wholesale drug license not cover mainland suppliers?
- Hawaii writes the license around presence rather than the shipping event. The Board of Pharmacy’s application instructions state that an entity licensed in its state of domicile with no facility, office, or vendor-managed inventory located in Hawaii is not required to obtain the Hawaii wholesale drug distributor license. A distributor that does operate a Hawaii facility is licensed by the Board after a Department of Health, Food and Drug Branch inspection. In either case the obligation sits with the supplier, not the buying practice.
- Can a nurse practitioner run a practice in Hawaii without a physician?
- Hawaii recognizes advanced practice registered nurses as independently practicing licensees under HRS chapter 457, with prescriptive authority granted by the Board of Nursing. An APRN-led practice can evaluate and order within its own scope. A medical director is still needed where a procedure falls outside APRN scope or where a payer requires one.
- Does my Hawaii clinic need a wholesale license to buy exosomes?
- No. Wholesale drug distributor licensure is a supplier-side obligation, and Hawaii’s version attaches to in-state facilities. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How does the general excise tax treat resale purchases?
- Hawaii levies a general excise tax on the seller rather than a sales tax on the buyer. A practice purchasing for resale provides a resale certificate so the wholesale rate applies to the transaction, and registers with the Department of Taxation. A practice purchasing products for use in its own services does not need one.
- How long does cold-chain shipping take to Hawaii?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure. Neighbor island addresses can add a connection within the carrier network, so Maui, Kauai, and Hawaii Island practices do well to order early in the week.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Hawaii Board of Pharmacy (accessed 16 October 2026)
- Hawaii Board of Pharmacy, wholesale prescription drug distributor requirements and instructions (PWD-00) (accessed 16 October 2026)
- Hawaii Medical Board (accessed 16 October 2026)
- Hawaii Board of Nursing, statutes and rules (accessed 16 October 2026)
- Hawaii Department of Health, Food and Drug Branch (accessed 16 October 2026)
- Hawaii Department of Taxation (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The field’s current characterization and reporting standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page says travels with every island shipment.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark EV characterization standard that MISEV2023 updates; together they define what a complete exosome characterization package contains, which is what the documentation standard on this page refers to.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: ISEV criteria for identifying MSC-derived small extracellular vesicles, the source-material category behind the perinatal MSC-EV products this page describes and the identity attributes their characterization reports.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.